Jeong Seogsong, Ge Yang, Chen Jing, Gao Qiang, Luo Guijuan, Zheng Bo, Sha Meng, Shen Feng, Cheng Qingbao, Sui Chengjun, Liu Jingfeng, Wang Hongyang, Xia Qiang, Chen Lei
Department of Liver Surgery, School of Medicine, Renji Hospital, Shanghai Jiao Tong University, Shanghai, China.
International Cooperation Laboratory on Signal Transduction, Eastern Hepatobiliary Surgery Institute, Second Military Medical University, Shanghai, China.
Front Oncol. 2020 Feb 19;10:143. doi: 10.3389/fonc.2020.00143. eCollection 2020.
Artificial Intelligence (AI) frameworks have emerged as a novel approach in medicine. However, information regarding its applicability and effectiveness in a clinical prognostic factor setting remains unclear. The AI framework was derived from a pooled dataset of intrahepatic cholangiocarcinoma (ICC) patients from three clinical centers ( = 1,421) by applying the TensorFlow deep learning algorithm to Cox-indicated pathologic (four), serologic (six), and etiologic (two) factors; this algorithm was validated using a dataset of ICC patients from an independent clinical center ( = 234). The model was compared to the commonly used staging system (American Joint Committee on Cancer; AJCC) and methodology (Cox regression) by evaluating the brier score (BS), integrated discrimination improvement (IDI), net reclassification improvement (NRI), and area under curve (AUC) values. The framework (BS, 0.17; AUC, 0.78) was found to be more accurate than the AJCC stage (BS, 0.48; AUC, 0.60; IDI, 0.29; NRI, 11.85; < 0.001) and the Cox model (BS, 0.49; AUC, 0.70; IDI, 0.46; NRI, 46.11; < 0.001). Furthermore, hazard ratios greater than three were identified in both overall survival (HR; 3.190; 95% confidence interval [CI], 2.150-4.733; < 0.001) and disease-free survival (HR, 3.559; 95% CI, 2.500-5.067; < 0.001) between latent risk and stable groups in validation. In addition, the latent risk subgroup was found to be significantly benefited from adjuvant treatment (HR, 0.459; 95% CI, 0.360-0.586; < 0.001). The AI framework seems promising in the prognostic estimation and stratification of susceptible individuals for adjuvant treatment in patients with ICC after resection. Future prospective validations are needed for the framework to be applied in clinical practice.
人工智能(AI)框架已成为医学领域的一种新方法。然而,关于其在临床预后因素设定中的适用性和有效性的信息仍不明确。通过将TensorFlow深度学习算法应用于Cox指标的病理(4个)、血清学(6个)和病因学(2个)因素,从三个临床中心的肝内胆管癌(ICC)患者汇总数据集(n = 1421)中得出AI框架;该算法使用来自独立临床中心的ICC患者数据集(n = 234)进行了验证。通过评估布里尔评分(BS)、综合判别改善(IDI)、净重新分类改善(NRI)和曲线下面积(AUC)值,将该模型与常用的分期系统(美国癌症联合委员会;AJCC)和方法(Cox回归)进行比较。发现该框架(BS,0.17;AUC,0.78)比AJCC分期(BS,0.48;AUC,0.60;IDI,0.29;NRI,11.85;P < 0.001)和Cox模型(BS,0.49;AUC,0.70;IDI,0.46;NRI,46.11;P < 0.001)更准确。此外,在验证中,潜在风险组和稳定组之间的总生存期(HR;3.190;95%置信区间[CI],2.150 - 4.733;P < 0.001)和无病生存期(HR,3.559;95% CI,2.500 - 5.067;P < 0.001)中均确定了大于3的风险比。此外,发现潜在风险亚组从辅助治疗中显著获益(HR,0.459;95% CI,0.360 - 0.586;P < 0.001)。AI框架在预测估计和对切除术后ICC患者辅助治疗易感个体进行分层方面似乎很有前景。该框架需要未来的前瞻性验证才能应用于临床实践。